Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's “Neurogenic Detrusor Overactivity Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Neurogenic Detrusor Overactivity, historical and forecasted epidemiology as well as the Neurogenic Detrusor Overactivity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Neurogenic Detrusor Overactivity Market by downloading the comprehensive report from DelveInsight @ Neurogenic Detrusor Overactivity Market
Key Takeaways from the Neurogenic Detrusor Overactivity Market Report
- The growth of the Neurogenic Detrusor Overactivity Market is expected to be primarily driven by increasing prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies.
- In September 2024:- Astellas Pharma- A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula-Based Suspension in Children From 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity.
- In September 2024:- EG 427- First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization.
- Neurogenic Detrusor Overactivity is estimated to affect 50–90% of patients with multiple sclerosis and 70–84% of patients with SCI.
- Neurogenic Detrusor Overactivity in children can be caused by various conditions, including transverse myelitis, spinal cord injury, and spina bifida. Spina bifida is the most common cause, affecting 1,500–2,000 of the over 4 million babies born annually in the US.
- It was found that the prevalence of urinary incontinence was 50.9% in patients with MS, 52.3% with SCI, 33.1% with Parkinson's disease, and 23.6% with stroke.
- The prevalence of urinary symptoms in patients with Parkinson's disease was found to be nearly3% for detrusor hyperreflexia with detrusor-sphincter dyssynergia in Japan.
- The prevalence of detrusor hyperreflexia in patients with Parkinson's disease was found to be approximately 7.7% in Italy.
- The leading Neurogenic Detrusor Overactivity Companies such as Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
- Promising Neurogenic Detrusor Overactivity Therapies such as Mirabegron, Vibegron, EG110A, and others.
Gain a competitive edge in the Neurogenic Detrusor Overactivity Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Neurogenic Detrusor Overactivity Treatment Drugs
Neurogenic Detrusor Overactivity Epidemiology Segmentation in the 7MM
- Total Neurogenic Detrusor Overactivity Prevalent Cases
- Total Neurogenic Detrusor Overactivity Diagnosed Prevalent Cases
- Neurogenic Detrusor Overactivity Condition-specific Diagnosed Prevalent Cases
- Neurogenic Detrusor Overactivity Treated Cases
Neurogenic Detrusor Overactivity Market Insights
The primary management of NDO focuses on behavioral approaches, such as increasing the frequency of urination, reducing fluid intake in the evening, avoiding diuretics like caffeine and alcohol, and using absorbent undergarments or bed pads. Pharmacologic treatments are the next step in managing NDO. Anticholinergic medications are commonly used, as they reduce detrusor muscle activation by blocking cholinergic muscarinic receptors. These drugs are available in both oral and transdermal forms, but they are nonspecific and can cause systemic side effects such as dry eyes, dry mouth, and visual disturbances due to ciliary muscle paralysis. Gastrointestinal effects like reduced motility and secretion can result in halitosis, dental caries, and constipation. Additionally, anticholinergic therapy may decrease sweating, which can be particularly problematic for multiple sclerosis patients who already experience heat intolerance.
Discover key developments and opportunities in the Neurogenic Detrusor Overactivity Market. Click here to learn more from DelveInsight’s latest report @ Neurogenic Detrusor Overactivity Market Size
Neurogenic Detrusor Overactivity Drugs Uptake
- DYSPORT (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. DYSPORT is approved for the management of urinary incontinence in adults with NDO due to SCI or multiple sclerosis in multiple countries including the UK and others.
- BOTOX is a neuromuscular blocking agent and acetylcholine release inhibitor used for managing neurogenic detrusor overactivity (NDO) in pediatric patients aged 5 years and older who do not respond adequately to or are intolerant of anticholinergic medications. It is the first neurotoxin approved specifically for this indication.
- MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ S (mirabegron extended-release oral suspension granules) are beta-3 adrenergic agonists indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older in the US. Additionally, mirabegron is marketed under the brand name BETMIGA for the treatment of NDO.
Neurogenic Detrusor Overactivity Emerging Drugs Profile
- EG110A: EG 427
EG110A is a recombinant herpes simplex virus type 1 (HSV-1)-derived vector that does not replicate and expresses the light chain of botulinum neurotoxin F (BoNT/F-LC) under the control of the human calcitonin gene-related peptide (hCGRP) promoter. It is designed to provide long-term, sensory neuron-selective transgenic expression in bladder afferents.
Download DelveInsight’s Neurogenic Detrusor Overactivity Market report today and stay ahead in this rapidly evolving field. @ Neurogenic Detrusor Overactivity Clinical Trials
Scope of the Neurogenic Detrusor Overactivity Market Report
- Coverage- 7MM
- Neurogenic Detrusor Overactivity Companies- Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
- Neurogenic Detrusor Overactivity Therapies- Mirabegron, Vibegron, EG110A, and others.
- Neurogenic Detrusor Overactivity Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Neurogenic Detrusor Overactivity Unmet Needs, KOL's views, Analyst's views, Neurogenic Detrusor Overactivity Market Access and Reimbursement
Download the report to understand which factors are driving Neurogenic Detrusor Overactivity Market Trends @ Neurogenic Detrusor Overactivity Market Trends
Table of Content
1. Key Insights
2. Executive Summary of Neurogenic Detrusor Overactivity
3. Competitive Intelligence Analysis for Neurogenic Detrusor Overactivity
4. Neurogenic Detrusor Overactivity: Market Overview at a Glance
5. Neurogenic Detrusor Overactivity: Disease Background and Overview
6. Patient Journey
7. Neurogenic Detrusor Overactivity Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Neurogenic Detrusor Overactivity Unmet Needs
10. Key Endpoints of Neurogenic Detrusor Overactivity Treatment
11. Neurogenic Detrusor Overactivity Marketed Products
12. Neurogenic Detrusor Overactivity Emerging Therapies
13. Neurogenic Detrusor Overactivity: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neurogenic Detrusor Overactivity
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
